Objective: This study evaluated the efficacy and tolerability of desvenlafaxine succinate
(desvenlafaxine) in the treatment of major depressive disorder (MDD). Method: In this 8 …

Objective: This study evaluated the efficacy and safety of desvenlafaxine succinate extended-
release in major depressive disorder (MDD). Method: Adult outpatients with DSM-IV–defined …

Introduction: The safety and tolerability profiles of antidepressants can often influence the
treatment choices of clinicians treating major depressive disorder. The purpose of this …

Purpose This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50
and 100 mg versus placebo across age groups and severity of depression at baseline in …

Objective: To assess short-term efficacy and safety of desvenlafaxine 50 and 100 mg/d
versus placebo for treating major depressive disorder (MDD). Assessment of sexual function …

Introduction: This research compares the efficacy and safety of desvenlafaxine
(administered as desvenlafaxine succinate) versus placebo in treating major depressive …

The efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine
succinate) were evaluated in two similarly designed, phase 3, randomized, double-blind …

Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin
norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major …

The antidepressant efficacy and safety of desvenlafaxine succinate (desvenlafaxine) were
evaluated in a phase III, double-blind, placebo-controlled study. Outpatients with a primary …

Objective: To evaluate the effects of desvenlafaxine therapy on functioning and well-being in
major depressive disorder (MDD). Method: Total and individual item Sheehan Disability …